Protocol Ledger

NCT05004064 · Phase II · ACTIVE NOT RECRUITING

Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma

Interventional Phase II clinical trial protocol NCT05004064 sponsored by University College, London in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-11-30 Enrollment: 48 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05004064
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)48 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05004064
Protocol FieldVerified Registry Value
NCT IdentifierNCT05004064
Consolidated Lead SponsorUniversity College, London
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment48 participants (ESTIMATED)
Registered Start Date2023-11-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05004064
Hospital Research SiteLocationSite Profile
University Hospital of WalesCardiff, United KingdomOpen Hospital Dossier ->
Beatson West of Scotland Cancer CentreGlasgow, United KingdomOpen Hospital Dossier ->
St Bartholomew's HospitalLondon, United KingdomOpen Hospital Dossier ->
University College London HospitalLondon, United KingdomOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI